Eli Lilly and Co., US5324571083

Eli Lilly and Co. stock: Health Canada clears Mounjaro use

Published on 11/20/2026 at 16:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Eli Lilly and Co. stock traded at EUR 1,242.60 on Lang & Schwarz at 16:05 CET Friday, November 20. Health Canada's November 18 decision expands Mounjaro's Canadian use.

Canada widens Mounjaro's role

  • Health Canada approved Mounjaro for reducing cardiovascular death, non-fatal heart attack and non-fatal stroke risks in eligible adults.
  • The decision followed a cardiovascular outcomes study involving more than 13,000 participants.
  • Lilly also expects its oral medicine Foundayo to reach Canadian pharmacies in January 2027.
Eli Lilly and Co., US5324571083, Illustration mit AI erstellt.

Health Canada approved Mounjaro on November 18 to reduce the risk of cardiovascular death, non-fatal heart attack and non-fatal stroke in adults with type 2 diabetes and established cardiovascular disease. Swikblog reported that Lilly Canada announced the decision, which followed a cardiovascular outcomes study involving more than 13,000 participants.

Eli Lilly and Co. stock traded at EUR 1,242.60 on Lang & Schwarz at 16:05 CET on Friday, November 20, 2026, 0.65% above the Xetra close of Thursday, November 19. The Canadian label expansion gives Lilly's tirzepatide franchise an additional cardiovascular-use angle alongside its established role in blood-sugar management.

What the approval changes

The decision broadens the circumstances in which physicians in Canada can consider Mounjaro for patients facing serious cardiovascular risks. Lilly Canada President Mathilde Merlet said the approval builds on the medicine's existing role in blood-sugar management, according to the cited report.

The new indication adds a regulatory development to Lilly's broader cardiometabolic portfolio. Investors will weigh its commercial relevance against pricing, access and execution considerations as the company expands the use of its incretin medicines.

Canada also authorized Lilly's oral GLP-1 medicine Foundayo, orforglipron, for weight management in eligible adults and for type 2 diabetes on November 13. Lilly expects the tablets to reach Canadian pharmacies in January 2027, according to the same report.

US-listed Eli Lilly and Co. stock was also shaped by the wider market session. Current market reports provide broader trading context.

More news and analyses on Eli Lilly and Co. stock.

Eli Lilly and Company

  • ISIN: US5324571083
  • Ticker: LLY
  • Primary exchange: New York Stock Exchange
  • Lang & Schwarz price: EUR 1,242.60 at 16:05 CET on November 20, 2026
  • Xetra close: EUR 1,234.60 on November 19, 2026
Disclaimer...
en | US5324571083 | ELI LILLY AND CO. | boerse | 70540371 | bgmi